<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="pmc-domain-id">2029</journal-id><journal-id journal-id-type="pmc-domain">bmri</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC3686056</article-id><article-id pub-id-type="pmcid-ver">PMC3686056.1</article-id><article-id pub-id-type="pmcaid">3686056</article-id><article-id pub-id-type="pmcaiid">3686056</article-id><article-id pub-id-type="pmid">23862154</article-id><article-id pub-id-type="doi">10.1155/2013/743509</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>A History of the Development of <italic toggle="yes">Brucella</italic> Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Avila-Calder&#243;n</surname><given-names initials="ED">Eric Daniel</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lopez-Merino</surname><given-names initials="A">Ahid&#233;</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sriranganathan</surname><given-names initials="N">Nammalwar</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boyle</surname><given-names initials="SM">Stephen M.</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Contreras-Rodr&#237;guez</surname><given-names initials="A">Araceli</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Departamento de Microbiolog&#237;a, Escuela Nacional de Ciencias Biol&#243;gicas, Instituto Polit&#233;cnico Nacional, Prolongaci&#243;n Carpio y Plan de Ayala s/n, Col. Sto. Tom&#225;s, 11340 M&#233;xico, DF, Mexico</aff><aff id="I2"><sup>2</sup>Center for Molecular Medicine and Infectious Diseases, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060, USA</aff><author-notes><corresp id="cor1">*Araceli Contreras-Rodr&#237;guez: <email>aracelicontreras21@gmail.com</email></corresp><fn fn-type="other"><p>Academic Editor: Adolfo Paz Silva</p></fn></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>3</day><month>6</month><year>2013</year></pub-date><volume>2013</volume><issue-id pub-id-type="pmc-issue-id">220024</issue-id><elocation-id>743509</elocation-id><history><date date-type="received"><day>11</day><month>1</month><year>2013</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2013</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>06</month><year>2013</year></date></event><event event-type="pmc-live"><date><day>16</day><month>07</month><year>2013</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-16 03:25:18.847"><day>16</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2013 Eric Daniel Avila-Calder&#243;n et al.</copyright-statement><copyright-year>2013</copyright-year><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BMRI2013-743509.pdf"/><abstract><p>Brucellosis is a worldwide zoonosis affecting animal and human health. In the last several decades, much research has been performed to develop safer <italic toggle="yes">Brucella</italic> vaccines to control the disease mainly in animals. Till now, no effective human vaccine is available. The aim of this paper is to review and discuss the importance of methodologies used to develop <italic toggle="yes">Brucella</italic> vaccines in pursuing this challenge.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Brucellosis is a zoonosis affecting approximately 500,000 people annually around the world. The disease remains endemic in many regions of the world including Latin America, Middle East, Africa, Asia, and the Mediterranean basin [<xref rid="B1" ref-type="bibr">1</xref>]. <italic toggle="yes">Brucella </italic>can be acquired by humans when they come in direct contact with fluid discharges from an infected animal, but in endemic regions people usually get infected through the consumption of unpasteurized dairy products mainly goat's milk and fresh soft cheese made out of unpasteurized milk. Isolation of <italic toggle="yes">Brucella</italic> is the gold standard to confirm infection; however, this is time-consuming and requires skilled technicians. Also, the handling of samples containing bacterial pathogen represents a high risk for laboratory personnel, for example, brucellosis is the most common bacterial laboratory-acquired infection worldwide [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. Therefore, brucellosis is generally diagnosed based on serological tests, in both animals and humans. However, human brucellosis is often misdiagnosed and underreported basically because the flu-like symptoms are protean and not specific. The treatment of human brucellosis requires the prolonged use of combination of antibiotics [<xref rid="B3" ref-type="bibr">3</xref>]. <italic toggle="yes">Brucella</italic> as facultative intracellular pathogen establishes an intimate relationship with the immune cells of the host. Through the subversion of the immune system, the pathogen is able to maintain a chronic infection that often makes treatment and diagnosis difficult. In the last decades, much research has been conducted in an attempt to develop safer and more effective <italic toggle="yes">Brucella</italic> vaccines for animals. There is no licensed vaccine for prevention of human brucellosis. A human vaccine would be useful to protect farmers, veterinarians, animal care workers, laboratory personnel, and general population living in endemic brucellosis areas [<xref rid="B2" ref-type="bibr">2</xref>]. The aim of this paper is to review and discuss the importance of the development of <italic toggle="yes">Brucella</italic> vaccines and some of the current methodologies used to pursue this goal.</p></sec><sec id="sec2"><title>2. Background</title><p>Research focused on the development of an ideal <italic toggle="yes">Brucella</italic> vaccine to prevent brucellosis in animals and humans has been sought since the beginning of twentieth century [<xref rid="B4" ref-type="bibr">4</xref>]. Live vaccines as well as inactivated ones have been developed; nevertheless, modified live vaccines have been shown to be superior protective immunogens as is the case with most diseases caused by facultative intracellular pathogens. </p><p>The attenuated live vaccine <italic toggle="yes">B. suis</italic> strain 2 was extensively used in several animals species in China. This vaccine did not induce persistent antibodies. <italic toggle="yes">B. abortus</italic> strain 104-M was developed in China and used as vaccine in humans. This vaccine was reported to be stable in antigenic structure, virulence, and immunogenicity [<xref rid="B4" ref-type="bibr">4</xref>]. Immunity derived from the use of live attenuated vaccines tends to be cell mediated and long lasting. Also, as they are administered live, the organism is allowed to replicate within the host allowing <italic toggle="yes">in vivo</italic> gene expression, thus making them less expensive [<xref rid="B5" ref-type="bibr">5</xref>]. </p><p>Two live attenuated vaccines strains were selected for their safety, stability, and immunogenicity for human protection. In 1952, <italic toggle="yes">B. abortus</italic> VA 19 was used in a mass epidemiological campaign in the former USSR, while in China <italic toggle="yes">B. abortus</italic> 104&#8201;M was tested in humans by intradermal, oral, and nasal routes [<xref rid="B6" ref-type="bibr">6</xref>]. </p><p>Over the years, a wide variety of killed vaccines have been developed for protection against brucellosis. They have had limited acceptance and success. None have approached the protection levels afforded by the live attenuated vaccines. Examples of killed vaccines are <italic toggle="yes">B. abortus </italic>strain 45/20 and <italic toggle="yes">B. melitensis </italic>H38 [<xref rid="B7" ref-type="bibr">7</xref>]. <italic toggle="yes">B. abortus </italic>strain 45/20 was used in cattle and sheep, while <italic toggle="yes">B. melitensis</italic> H38 was tested in mice and cows. In addition to the lack of sufficient protection after challenge, killed vaccines such as strains 45/20 and H38 can induce persistent antibody titers. Killed vaccines for humans were first used in Malta in 1906 by Eyre, who vaccinated 51 soldiers [<xref rid="B6" ref-type="bibr">6</xref>]. </p><p>Several antigenic fractions extracted from <italic toggle="yes">Brucella</italic> have been tested as a vaccine candidates, mainly in association with a variety of adjuvants; some of them included cell envelopes [<xref rid="B8" ref-type="bibr">8</xref>], outer membrane proteins [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>], insoluble residues of hot sodium dodecyl sulfate (SDS) extracts of cell envelopes (PG) [<xref rid="B9" ref-type="bibr">9</xref>], phenol insoluble fraction (PI) [<xref rid="B10" ref-type="bibr">10</xref>], soluble SDS extracts [<xref rid="B11" ref-type="bibr">11</xref>], <italic toggle="yes">Brucella</italic> soluble antigens (BASA) [<xref rid="B12" ref-type="bibr">12</xref>], periplasmic proteins and salt extractable proteins [<xref rid="B13" ref-type="bibr">13</xref>], chemically modified <italic toggle="yes">Brucella</italic> proteins [<xref rid="B14" ref-type="bibr">14</xref>], smooth and rough LPS [<xref rid="B15" ref-type="bibr">15</xref>], recombinant Cu-Zn superoxide dismutase (SOD), and synthetic peptides [<xref rid="B16" ref-type="bibr">16</xref>], among others. From all these fractions, only the phenol insoluble (PI) fraction has been used in humans [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B17" ref-type="bibr">17</xref>]. PI was an extract from the cell wall of <italic toggle="yes">B. melitensis</italic>. PI was applied subcutaneously in two doses of 1&#8201;mg with 15 hours interval. In humans, this vaccine showed low toxicity, hypersensitivity, and good immune response. The PI vaccine was used massively in 1967 in 800 laboratory workers who were often in contact with the bacteria. It was reported that all of them were protected except one who had immunodeficiency. The protection conferred by PI lasted around 18 to 24 months [<xref rid="B18" ref-type="bibr">18</xref>].</p></sec><sec id="sec3"><title>3. Current Vaccines for the Prevention of Animal Brucellosis</title><p>Vaccination is probably the most economic measure for control of brucellosis in endemic areas. Many countries have developed control measures for the eradication of the disease in livestock animal. These programs minimized the economic losses due to the abortion, infertility, and weak offspring and decreased milk production [<xref rid="B19" ref-type="bibr">19</xref>]. Presently, the vaccination programs are based on control of brucellosis mainly due to <italic toggle="yes">B. melitensis</italic> and <italic toggle="yes">B. abortus </italic>[<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>].</p><p>Females are the most important targets for the vaccination programs as some vaccines cause severe tissue damage in male and lateral or vertical transmission occurs mainly via fluids associated with abortion or birth of infected calves or through shedding in milk. Vaccination by intramuscular or subcutaneous route is the most frequently used in livestock, but also the intraconjunctival route also has been used with good results [<xref rid="B19" ref-type="bibr">19</xref>]. </p><p>Currently, only three live attenuated vaccines for the control of <italic toggle="yes">B. abortus </italic>infection in cattle are recommended: <italic toggle="yes">B. abortus</italic> 45/20, <italic toggle="yes">B. abortus</italic> strain 19 (S19), and <italic toggle="yes">B. abortus</italic> RB51 [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B22" ref-type="bibr">22</xref>]. <italic toggle="yes">B. abortus </italic>strain 45/20 was isolated following twenty passages in guinea pigs; this rough strain is used only as heat-killed vaccine to avoid reversion to a virulent strain. Also this vaccine needs to be administrated with an adjuvant in adult cattle; it does not interfere with serological diagnosis and it is safer in pregnant animals but only has been tested in some countries [<xref rid="B22" ref-type="bibr">22</xref>].</p><p>Another licensed live smooth attenuated vaccine for control of bovine brucellosis is <italic toggle="yes">B. abortus </italic>S19. This strain was isolated in the early twentieth century and was naturally attenuated when a virulent culture of <italic toggle="yes">B. abortus </italic>was left at room temperature for one year [<xref rid="B23" ref-type="bibr">23</xref>]. <italic toggle="yes">B. abortus</italic> S19 has been effective for the control of brucellosis in adult bovines and prevents abortion as well as decreasing the prevalence in herds. However due to the smooth nature of the strain S19 and the strong antibody response against the O-side chain, it does not permit discrimination of infected from vaccinated animals. The competitive ELISA assay and radial immunodiffusion test have been used to permit differentiation between vaccinated or infected animals in field [<xref rid="B24" ref-type="bibr">24</xref>]. A low rate of abortion in livestock and significant reduction in milk production has been reported with <italic toggle="yes">B. abortus</italic> S19 vaccination [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B22" ref-type="bibr">22</xref>]. </p><p>The live vaccine <italic toggle="yes">B. abortus </italic>RB51 is a spontaneous rough mutant obtained by subculturing the virulent strain <italic toggle="yes">B. abortus</italic> 2308 on medium containing rifampicin and penicillin [<xref rid="B25" ref-type="bibr">25</xref>]. Subsequently, it was found to contain an IS711 element disrupting the <italic toggle="yes">wbo</italic>A gene encoding a glycosyl transferase responsible for O-side chain synthesis [<xref rid="B26" ref-type="bibr">26</xref>]; hence it has a rough phenotype. In contrast to strain 45/20, <italic toggle="yes">B. abortus</italic> RB51 is very stable and it is currently used in many countries instead of <italic toggle="yes">B. abortus</italic> S19. Rough strain RB51 is less virulent and it does not induce a positive response in typical serological diagnostic test [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B25" ref-type="bibr">25</xref>]. Vaccination of pregnant cows with strain RB51 can induce low levels of abortion (less than 0.2%); however it is safe at lower doses during pregnancy [<xref rid="B27" ref-type="bibr">27</xref>]. Vaccine strain RB51 can infect humans but it is less virulent than strain S19 [<xref rid="B28" ref-type="bibr">28</xref>]. </p><p>Currently, the live vaccine <italic toggle="yes">B. melitensis </italic>Rev. 1 is used for the control of brucellosis in small ruminants. This strain was developed by Herzberg and Elberg in mid-1950s and retains the common characteristics of the <italic toggle="yes">Brucella </italic>species, but it is resistant to 2.5&#8201;<italic toggle="yes">&#956;</italic>g/mL streptomycin and susceptible to 5&#8201;IU penicillin G that allows differentiation from field strains [<xref rid="B29" ref-type="bibr">29</xref>]. Subcutaneous or conjunctival immunization with <italic toggle="yes">B. melitensis</italic> Rev. 1 confers adequate immunity in small ruminants. <italic toggle="yes">B. melitensis</italic> Rev. 1 induces a positive antibody response in serological tests in vaccinated animals. Also <italic toggle="yes">B. melitensis</italic> Rev. 1 can infect humans. The vaccination is recommended prior to the first gestation between 3 and 7 months of age to avoid abortion in pregnant animals [<xref rid="B30" ref-type="bibr">30</xref>]. As <italic toggle="yes">B. melitensis</italic> can be isolated from cattle, some scientists proposed use of the live attenuated vaccine <italic toggle="yes">B. melitensis</italic> Rev. 1 to control the disease in cattle [<xref rid="B30" ref-type="bibr">30</xref>].</p><p>Compared to the extensive research effort for developing new vaccines against <italic toggle="yes">B. melitensis </italic>or <italic toggle="yes">B. abortus</italic>, little research has been conducted to protect swine against <italic toggle="yes">B. suis</italic> [<xref rid="B31" ref-type="bibr">31</xref>]. Oral or intramuscular vaccination with strain RB51, killed <italic toggle="yes">B. suis</italic>, or purified O-polysaccharide was reported to be efficacious in protecting swine exposed to infected boars [<xref rid="B29" ref-type="bibr">29</xref>]. However, other studies have shown very little protection by strain RB51 in immunized swine against wild type challenge [<xref rid="B19" ref-type="bibr">19</xref>].</p></sec><sec id="sec4"><title>4. Brucellosis Eradication Programs</title><p>The general strategies proposed in 1998 by the WHO including Mediterranean Zoonoses Control Program to eradicate animal brucellosis were the following: (i) prevention of spread between animals and monitoring of brucellosis-free herds and zones, (ii) elimination of infected animals by test and slaughter programs to obtain brucellosis-free herds and regions, and (iii) vaccination to reduce the prevalence [<xref rid="B32" ref-type="bibr">32</xref>].</p><p>Due to the lack of a human vaccine against brucellosis, animal vaccination is a critical factor for the control and eradication of brucellosis in animals and humans. However this approach could be complemented with surveillance of livestock and/or elimination of infected animals as well as other critical control measures.</p><p>Regulatory programs for brucellosis are influenced by the prevalence of the disease in livestock or humans and economic considerations. The majority of programs for the eradication of animal brucellosis are aimed at reducing the prevalence that include test and removal programs, sanitization, and/or vaccination [<xref rid="B19" ref-type="bibr">19</xref>].</p><p>In general, sanitization programs are based on the education of the producers for elimination of contaminated material, decontamination, and other methods to avoid exposure and the dissemination of the disease agent. Test and removal programs are applicable in areas with high prevalence but not for eradication programs, and this should be stricter in surveillance herds of individual livestock [<xref rid="B19" ref-type="bibr">19</xref>]. However for developing countries, the elimination of the <italic toggle="yes">Brucella</italic>-infected animals is not affordable. </p><p>In endemic regions where the prevalence of brucellosis was low and vaccination was stopped, outbreaks of human and animal brucellosis were reported [<xref rid="B33" ref-type="bibr">33</xref>].</p><p>In 2001, Brazil implemented control measures for eradication of bovine brucellosis, which included vaccination of the cows aged 3&#8211;8 months with <italic toggle="yes">B. abortus</italic> S19, accreditation of brucellosis-free herds, periodic surveillance, requirement of serological testing for movement or entry of livestock fairs, and compulsory slaughter of animals positive for brucellosis and permanent refresher training for accredited veterinarians [<xref rid="B21" ref-type="bibr">21</xref>]. It is clear that for the successful eradication and control programs for brucellosis in endemic areas, the government should be involved. They can raise the awareness of the risk of the disease, while also raising specific concern about infecting individual human subjects and the potential risk of horizontal transfer in the field. To circumvent these problems, the national veterinary services needed to maintain a certain level of competence as well as adopt a method to identify and register vaccinated animals. </p><p>In the Middle East, brucellosis has been reported in almost all domestic animals, particularly cattle, sheep, and goats. However, there is a controversy on the best choice of the strategy for the brucellosis control. In some countries, the test and slaughter policy together with the vaccination of the young females was adopted; in others, particularly with regard to sheep and goats, mass vaccination was utilized. Regardless, vaccination was limited to cattle and small ruminants. In several countries, little is done to control the disease in humans because of lack of financial and technical facilities [<xref rid="B34" ref-type="bibr">34</xref>].</p><p>In the case of <italic toggle="yes">B. suis</italic>, dissemination in swine is primarily the result of <italic toggle="yes">B. suis </italic>biovar 1 and 3, and some cases of transmission of biovar 2 from wild pig to domestic swine have been reported. Due to the low pathogenicity of biovar 2 in humans, it is not considered to be a significant zoonotic threat and therefore likely not to have an adequate serologic surveillance [<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>]. </p><p>Although <italic toggle="yes">B. ovis</italic> rarely causes abortion in ewes, the infection manifests with testicular lesions and reduced infertility in rams [<xref rid="B37" ref-type="bibr">37</xref>]. As epididymal lesions in rams are not pathognomonic for the infection by <italic toggle="yes">Brucella</italic>, surveillance relies on serodiagnosis and isolation of the bacteria from infected animals [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B38" ref-type="bibr">38</xref>].</p></sec><sec id="sec5"><title>5. Subunit Vaccines against Brucellosis</title><p>As we mentioned earlier, the use of the live-attenuated vaccines against brucellosis represents a risk due to its potential ability to revert to virulence, cause abortion in pregnant animals, and be shed in milk, but also live strains could infect people coming into contact with the vaccine for example, farmers, abattoir workers, and veterinarians.</p><p>An ideal vaccine for use either in humans or in animals should meet the following criteria: should be effective and avirulent and induce long-lasting protection [<xref rid="B39" ref-type="bibr">39</xref>].</p><p>Subunit vaccines, like recombinant proteins, are promising vaccine candidates because they are less biohazardous, well defined, avirulent, noninfectious, and nonviable [<xref rid="B40" ref-type="bibr">40</xref>].</p><p>For the development of an effective vaccine against brucellosis, it is necessary to elicit an adequate immunological response (biased towards a Th1) and then choose the best antigen that induces protective immunity. It is well known that for an intracellular pathogen represented by <italic toggle="yes">Brucella</italic>, the production of IFN<italic toggle="yes">&#947;</italic>, TNF<italic toggle="yes">&#945;</italic>, and IL-12 from the T helper cells (Th1 response), as well as CD8+ and CD4+ T lymphocytes, activated macrophages and dendritic cells are necessary for the control of the infection; whereas Th2 components have a minor role in the control of infection [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>]. There appear to be three mechanisms of the adaptive immune response against brucellosis that are important: (1) production of IFN (produced by CD4+, CD8+, and <italic toggle="yes">&#947;&#948;</italic> T cells) activates the bactericidal action of the macrophages to hamper the intracellular survival of <italic toggle="yes">Brucella</italic>; (2) the cytotoxic action of the CD8+ and <italic toggle="yes">&#947;&#948;</italic> T cells kills infected macrophages; (3) Th1 antibody IgG2a isotypes opsonize the bacteria to facilitate effective phagocytosis [<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B41" ref-type="bibr">41</xref>]. Subunit vaccines appear to be a promising option to develop safer vaccines because they are not able to regain virulence as opposed to live strains. However subunit vaccines also sometimes fail to elicit the magnitude of the immune response and/or induce protection comparable to live vaccines [<xref rid="B39" ref-type="bibr">39</xref>]. Since they tend to be poorly immunogenic stimulators, they require the coadministration of an adjuvant. Therefore the success of the subunit vaccine depends of the use of the substances endowed with immunomodulatory properties that control the selective induction of the appropriate type of antigenic-immune response. Moreover, the success of the subunit vaccine is associated with the route of administration [<xref rid="B42" ref-type="bibr">42</xref>].</p><sec id="sec5.1"><title>5.1. Recombinant Proteins</title><p>Selecting the optimal antigens represents the cornerstone in vaccine design. Depending on the desired response, the antigenic proteins should contain appropriate epitopes to B-cell receptors and can be recognized by the T-cell receptor in a complex with MHC molecules [<xref rid="B43" ref-type="bibr">43</xref>].</p><p>Numerous subunit fractions from <italic toggle="yes">Brucella</italic> have been examined as recombinant proteins vaccines in mouse model, and some of these have shown protective efficacy [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B39" ref-type="bibr">39</xref>].</p><p>Several <italic toggle="yes">Brucella </italic>immunogenic antigens have been found in the outer membrane of this Gram-negative pathogen. Bacterial cell surface antigens are prime candidates as they represent the initial point of contact between the pathogen and its host [<xref rid="B44" ref-type="bibr">44</xref>].</p><p>For instance, the recombinant 31&#8201;kDa outer membrane protein (Omp31) in aluminum hydroxide or Incomplete Freud Adjuvant (IFA) induced significant levels of protection against <italic toggle="yes">B. melitensis </italic>challenge in the mouse model [<xref rid="B45" ref-type="bibr">45</xref>]. Also the purified recombinant lipoproteins Omp16 and Omp19 induce significant protection against oral or systemic <italic toggle="yes">B. abortus </italic>challenge when delivered by a parental or oral route without adjuvant, yet by a different immune mechanism. Also plant-made vaccines expressing Omp16 or Omp19 were able to induce significant protective immune response when administrated to mice by the oral route as purified proteins and within the crude leaf material of transgenic tobacco plants [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B42" ref-type="bibr">42</xref>].</p><p>The Omp25 (a peptidoglycan-layer protein) is an important <italic toggle="yes">Brucella </italic>virulence factor involved in survival; <italic toggle="yes">B. melitensis</italic>, <italic toggle="yes">B. abortus</italic>, and <italic toggle="yes">B. ovis </italic>Omp25 deletion mutants are attenuated in mice [<xref rid="B46" ref-type="bibr">46</xref>]. As a recombinant protein, Omp25 from <italic toggle="yes">B. abortus </italic>S19 induced protection against <italic toggle="yes">B. abortus</italic> 544 challenge in mice when it was administrated by intradermal or intraperitoneal routes [<xref rid="B47" ref-type="bibr">47</xref>].</p><p>In contrast, three peptides from the periplasmic protein Cu-Zn superoxide dismutase from <italic toggle="yes">B. abortus </italic>were assayed for induction of protection in mice; however only one was able to induce significant protection against <italic toggle="yes">B. abortus </italic>2308 [<xref rid="B16" ref-type="bibr">16</xref>].</p><p>Also the cytosolic proteins SurA and DnaK were evaluated in mice as purified recombinant proteins. Both proteins induced similar levels of protection against <italic toggle="yes">B. abortus</italic> (moderate levels compared with the live vaccine control) [<xref rid="B48" ref-type="bibr">48</xref>].</p><p>Combining several antigens in a vaccine formulation does not always induce higher levels of protection compared to the use of a single antigen. The immunization with DnaK and SurA did not show a synergistic effect compared with the vaccination of either antigen alone [<xref rid="B48" ref-type="bibr">48</xref>]. A similar effect was observed when Omp31 and <italic toggle="yes">Brucella </italic>lumazine synthase (BSL) were used together versus individually. However, chimeric formulation of Omp31-BSL augmented the protection achieved by either single antigen [<xref rid="B49" ref-type="bibr">49</xref>].</p><p>The need of the appropriate adjuvant is also important for obtaining protection in case of subunit vaccines. When recombinant periplasmic protein P39 was combined with CpG oligonucleotides, the protein induced a Th1 response and protection against <italic toggle="yes">B. abortus</italic> [<xref rid="B50" ref-type="bibr">50</xref>]. Recently recombinant Omp28 from <italic toggle="yes">B. melitensis </italic>adjuvanted with CpG conferred moderate levels of protection in mice against <italic toggle="yes">B. abortus</italic> 544 challenge [<xref rid="B51" ref-type="bibr">51</xref>].</p></sec><sec id="sec5.2"><title>5.2. Vectored Vaccines</title><p>Antigen delivery systems become necessary when antigens are not efficiently transported to the appropriate sites or presented to the immune system. For example, rapid degradation can result in weak or virtual lack of responses to otherwise immunogenic antigens [<xref rid="B43" ref-type="bibr">43</xref>].</p><p>BP26 is a 26&#8201;kDa periplasmic protein with an unknown function. Recently, a vectored vaccine has been developed based on protein BP26 or Omp16 and Omp31; that is, <italic toggle="yes">E. coli</italic> expressing <italic toggle="yes">B. melitensis </italic>BP26 induced lymphocyte proliferation, IFN-<italic toggle="yes">&#947;</italic> production, and protection in mice. On the other hand <italic toggle="yes">E. coli </italic>(K12) may be an ideal vaccine platform with natural adjuvant properties since it is nonpathogenic and can delivery antigens to antigen-presenting cells promoting cellular immune responses [<xref rid="B52" ref-type="bibr">52</xref>].</p><p>
<italic toggle="yes">Lactococcus lactis</italic> expressing Cu-Zn SOD has also been used as a delivery system in mouse model and induced protection against a <italic toggle="yes">B. abortus</italic> challenge [<xref rid="B53" ref-type="bibr">53</xref>].</p><p>Semliki Forest Virus (SFV) was packed with RNA encoding the <italic toggle="yes">B. abortus </italic>Cu-Zn SOD and was able to induce protection in mice against <italic toggle="yes">B. abortus</italic> [<xref rid="B54" ref-type="bibr">54</xref>]. However, viral delivery systems do not always work, as in the case of the vaccinia virus delivering DNA encoding <italic toggle="yes">B. abortus</italic> GroEL (a chaperonin) or L7/L12 (ribosomal protein) was unable to induce a protective response against <italic toggle="yes">B. abortus </italic>challenge [<xref rid="B55" ref-type="bibr">55</xref>].</p></sec><sec id="sec5.3"><title>5.3. DNA Vaccines</title><p>DNA vaccines are able to induce both humoral and cellular immune responses. However, it is generally perceived that they induce less potent immune responses than protein vaccines [<xref rid="B39" ref-type="bibr">39</xref>]. Nevertheless, this may not be the case for brucellosis; for example, a DNA vaccine expressing Omp31 appears to elicit similar levels of protection as the recombinant protein combined with IFA [<xref rid="B56" ref-type="bibr">56</xref>]. Moreover, a BSL-DNA vaccine was more effective than the same recombinant protein against <italic toggle="yes">B. abortus </italic>challenge [<xref rid="B57" ref-type="bibr">57</xref>].</p><p>The use of the DNA vaccines resulted in the induction of a diverse immune response, which led to different levels of protection, which, in many cases, were not as high when compared with the commercial live attenuated <italic toggle="yes">Brucella </italic>vaccine [<xref rid="B21" ref-type="bibr">21</xref>].</p><p>Strategies to enhance the efficacy of DNA vaccines are constantly emerging to maximize immune responses. This is of particular importance in order to aid the transition of these vaccines into larger animal models and also humans [<xref rid="B39" ref-type="bibr">39</xref>].</p><p>One advantage of DNA vaccines is that multiple antigens can be expressed. A fusion of the antigens L7/L12 and Omp16 induced higher level of protection in mice than DNA vaccines expressing individual antigens [<xref rid="B58" ref-type="bibr">58</xref>]. Another study reported the fusion of L7/L12 and P39 genes (encoding ribosomal and periplasmic proteins, resp.) within a DNA vaccine that improved the protection compared with individual DNA vaccines encoding either alone [<xref rid="B59" ref-type="bibr">59</xref>].</p><p>In contrast, the coadministration of multiple plasmids expressing BSCP31 (31&#8201;kDa protein), Cu/Zn SOD, or L7/L12 strikingly enhanced the protection against <italic toggle="yes">B. abortus </italic>challenge compared with live vaccine <italic toggle="yes">B. abortus</italic> strain S19 [<xref rid="B60" ref-type="bibr">60</xref>].</p><p>Another strategy to improve brucellosis DNA vaccines is through the modulation of the immune response by the coexpression of cytokines as adjuvants [<xref rid="B21" ref-type="bibr">21</xref>]. When genes encoding IL-2 or IL-18 were fused to SOD and expressed in a single DNA vaccine, improved protection was observed compared to a SOD DNA vaccine alone [<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>]. In contrast, when IL-15 or IL-12 genes were coadministrated on separate plasmids along with the multigenic vaccine containing the <italic toggle="yes">bscp</italic>31, <italic toggle="yes">sod</italic>, and L7/L12 genes, their efficacy was increased against <italic toggle="yes">B. abortus</italic> challenge compared to that observed with live vaccine S19 [<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>].</p></sec><sec id="sec5.4"><title>5.4. Outer Membrane Vesicles: New Promising Vaccines against Brucellosis</title><p>Over 50 years ago, it was reported that Gram-negative bacteria shed outer membrane vesicles (OMVs) [<xref rid="B65" ref-type="bibr">65</xref>]. Production of these vesicles occurs spontaneously and during the normal growth of Gram-negative bacteria in many different environments including soil, biofilms, and enriched culture medium and during the infective process in the case of pathogens. As OMVs are shed from the outer membrane, their general composition has been characterized to contain outer membrane proteins, phosphoslipids, lipopolysaccharide (LPS), and some periplasmic compounds that are entrapped during the bulging of the outer membrane [<xref rid="B66" ref-type="bibr">66</xref>&#8211;<xref rid="B69" ref-type="bibr">69</xref>].</p><p>OMVs from the Gram-negative bacteria have been implicated in many processes including the release of virulence factors to the host as well as in the delivery of toxins, modulation of the immune system, trafficking of signaling molecules between bacterial cells, and biofilm formation [<xref rid="B67" ref-type="bibr">67</xref>&#8211;<xref rid="B69" ref-type="bibr">69</xref>]. Taking advantage of the immunomodulatory role of the OMVs from Gram-negative pathogens, the use of the OMVs as acellular vaccines against the OMVs-producing pathogens <italic toggle="yes">in vivo </italic>and <italic toggle="yes">in vitro</italic> has been tested [<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B70" ref-type="bibr">70</xref>].</p><p>
<italic toggle="yes">Brucella</italic> also release OMVs to the external milieu [<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>]. Recently, the use of <italic toggle="yes">Brucella</italic> OMVs as a potential vaccine has been explored. Purified OMVs from both <italic toggle="yes">B. melitensis </italic>strains 16&#8201;M (smooth strain) and VTRM1 (rough lacking O-side chain) by differential centrifugation were used to immunize mice. When <italic toggle="yes">Brucella</italic> OMVs were administrated by an intramuscular route, OMVs from both strains induced similar levels of protection against virulent <italic toggle="yes">B. melitensis </italic>challenge compared with the live vaccine <italic toggle="yes">B. melitensis</italic> Rev. 1. In contrast, rough OMVs induced better levels of IgG2a antibodies than OMVs from smooth and live vaccine strain [<xref rid="B73" ref-type="bibr">73</xref>].</p><p>To improve the immune responses and subsequent protection by <italic toggle="yes">Brucella </italic>OMVs, Pluronic-85 was used as adjuvant. This adjuvant enhances the immune response and the protection against challenge with virulent <italic toggle="yes">B. melitensis </italic>strain compared to OMVs alone [<xref rid="B74" ref-type="bibr">74</xref>].</p><p>Compared to other subunit vaccines, OMVs may possess considerable advantages. OMVs are multicomplex antigens due to their numerous bacterial components and are composed of bacterial phospholipids that can act as natural bacterial adjuvants. Recently, it has been demonstrated that OMVs can interact with the eukaryotic host cell and enter by endocytic pathways; OMVs from <italic toggle="yes">Brucella </italic>are not the exception [<xref rid="B75" ref-type="bibr">75</xref>]. Therefore not only can membrane receptor dependent-pathways be induced, but also cytoplasmic receptors such as NOD (nucleotide binding and oligomerization receptor) or others could help trigger an immune response.</p><p>Compared to recombinant proteins, DNA vaccine, or vectored vaccines, OMVs could be less expensive in terms of production and purification. OMVs are purified from the <italic toggle="yes">Brucella </italic>culture medium by differential centrifugation and washing [<xref rid="B73" ref-type="bibr">73</xref>].</p><p>Because the genome sequences of many <italic toggle="yes">Brucella</italic> species are available, this makes it possible to genetically modify the content of OMVs using recombinant DNA technology, for example, overexpression of protective antigens that are expressed <italic toggle="yes">in vivo</italic>. In this way, it should be possible to enhance the efficacy of <italic toggle="yes">Brucella</italic> OMVs as has been reported by others [<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>]. However, further research is essential to fully evaluate the benefits and risks of these types of acellular vaccines for the prevention of brucellosis in animals and especially humans.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>This work was funded by CONACYT CB-2011-01 no. 169259, SIP-IPN 20110891, SIP-IPN 20134610, and ICYTDF-IPN (Project of Investigation under the consolitadation of professors from Instituto Politecnico Nacional, with the level of National Research Candidates ICYTDF-IPN). Eric Daniel Avila-Calder&#243;n was supported by CONACYT and PIFI-IPN scholarships. Araceli Contreras-Rodr&#237;guez and Ahid&#233; Lopez-Merino were supported by fellowships from COFAA, SIP-EDI, and SNI-CONACYT.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>G</given-names></name><name name-style="western"><surname>Papadimitriou</surname><given-names>P</given-names></name><name name-style="western"><surname>Akritidis</surname><given-names>N</given-names></name><name name-style="western"><surname>Christou</surname><given-names>L</given-names></name><name name-style="western"><surname>Tsianos</surname><given-names>EV</given-names></name></person-group><article-title>The new global map of human brucellosis</article-title><source><italic toggle="yes">Lancet Infectious Diseases</italic></source><year>2006</year><volume>6</volume><issue>2</issue><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="other">2-s2.0-31344450203</pub-id><pub-id pub-id-type="pmid">16439329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(06)70382-6</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luna-Mart&#237;nez</surname><given-names>JE</given-names></name><name name-style="western"><surname>Mej&#237;a-Ter&#225;n</surname><given-names>C</given-names></name></person-group><article-title>Brucellosis in Mexico: current status and trend</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2002</year><volume>90</volume><issue>1&#8211;4</issue><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">12414130</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-1135(02)00241-9</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ariza</surname><given-names>J</given-names></name><name name-style="western"><surname>Bosilkovski</surname><given-names>M</given-names></name><name name-style="western"><surname>Cascio</surname><given-names>A</given-names></name><etal/></person-group><article-title>Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations</article-title><source><italic toggle="yes">PLoS Medicine</italic></source><year>2007</year><volume>4</volume><issue>12, article e317</issue><pub-id pub-id-type="other">2-s2.0-38048999578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.0040317</pub-id><pub-id pub-id-type="pmcid">PMC2222927</pub-id><pub-id pub-id-type="pmid">18162038</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Nicoletti</surname><given-names>P</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Nielsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>JR</given-names></name></person-group><article-title>Vaccination</article-title><source><italic toggle="yes">Animal Brucellosis</italic></source><year>1990</year><publisher-loc>Boca Raton, Fla, USA</publisher-loc><publisher-name>CRC Press</publisher-name><fpage>284</fpage><lpage>299</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Corbel</surname><given-names>MJ</given-names></name></person-group><article-title>Brucellosis vaccines: past, present and future</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2002</year><volume>90</volume><issue>1&#8211;4</issue><fpage>479</fpage><lpage>496</lpage><pub-id pub-id-type="other">2-s2.0-0037146685</pub-id><pub-id pub-id-type="pmid">12414166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-1135(02)00255-9</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Roux</surname><given-names>J</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Madkour</surname><given-names>MM</given-names></name></person-group><article-title>
<italic toggle="yes">Brucella</italic> vaccines in humans</article-title><source><italic toggle="yes">Brucellosis</italic></source><year>1989</year><publisher-loc>London, UK</publisher-loc><publisher-name>Butterworths</publisher-name><fpage>244</fpage><lpage>249</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plommet</surname><given-names>M</given-names></name><name name-style="western"><surname>Renoux</surname><given-names>G</given-names></name><name name-style="western"><surname>Philppon</surname><given-names>A</given-names></name><name name-style="western"><surname>Lorentz</surname><given-names>C</given-names></name><name name-style="western"><surname>Gestin</surname><given-names>J</given-names></name></person-group><article-title>Brucellose experimentale. I. Comparison de l&#8217;efficacite des vaccines B19 and H38 vaccine</article-title><source><italic toggle="yes">Annales de Recherches Veterinaires (Paris)</italic></source><year>1970</year><volume>1</volume><fpage>189</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">5003297</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montaraz</surname><given-names>JA</given-names></name><name name-style="western"><surname>Winter</surname><given-names>AJ</given-names></name></person-group><article-title>Comparison of living and nonliving vaccines for <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>1986</year><volume>53</volume><issue>2</issue><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="other">2-s2.0-0022468107</pub-id><pub-id pub-id-type="pmid">3089933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.53.2.245-251.1986</pub-id><pub-id pub-id-type="pmcid">PMC260865</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winter</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>GE</given-names></name></person-group><article-title>Comparative immune responses to native cell envelope antigens and the hot sodium dodecyl sulfate insoluble fraction (PG) of <italic toggle="yes">Brucella abortus</italic> in cattle and mice</article-title><source><italic toggle="yes">Veterinary Immunology and Immunopathology</italic></source><year>1988</year><volume>18</volume><issue>2</issue><fpage>149</fpage><lpage>163</lpage><pub-id pub-id-type="other">2-s2.0-0023936644</pub-id><pub-id pub-id-type="pmid">3133872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0165-2427(88)90057-8</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roux</surname><given-names>J</given-names></name><name name-style="western"><surname>Serre</surname><given-names>A</given-names></name></person-group><article-title>Prophylaxie individuelle et vaccination contre les brucelloses humaines par une fraction antig&#233;nique de <italic toggle="yes">Brucella melitensis</italic> (complexe proteines-glycoproteines-glycosaminopeptides)</article-title><source><italic toggle="yes">Revue d'&#233;pid&#233;miologie, M&#233;decine Sociale et Sant&#233; Publique</italic></source><year>1971</year><volume>19</volume><fpage>503</fpage><lpage>516</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterne</surname><given-names>M</given-names></name><name name-style="western"><surname>Trim</surname><given-names>G</given-names></name><name name-style="western"><surname>Broughton</surname><given-names>ES</given-names></name></person-group><article-title>Immunisation of laboratory animals and cattle with non-agglutinogenic extracts of <italic toggle="yes">Brucella abortus</italic> strain 45-20</article-title><source><italic toggle="yes">Journal of Medical Microbiology</italic></source><year>1971</year><volume>4</volume><issue>2</issue><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="other">2-s2.0-0015063554</pub-id><pub-id pub-id-type="pmid">4998854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/00222615-4-2-185</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dzata</surname><given-names>GK</given-names></name><name name-style="western"><surname>Confer</surname><given-names>AW</given-names></name><name name-style="western"><surname>Wyckoff</surname><given-names>JH</given-names></name></person-group><article-title>The effects of adjuvants on immune responses in cattle injected with a <italic toggle="yes">Brucella abortus</italic> soluble antigen</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>1991</year><volume>29</volume><issue>1</issue><fpage>27</fpage><lpage>48</lpage><pub-id pub-id-type="other">2-s2.0-0025813041</pub-id><pub-id pub-id-type="pmid">1835213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0378-1135(91)90108-r</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pugh</surname><given-names>GW</given-names></name><name name-style="western"><surname>Tabatabai</surname><given-names>LB</given-names></name></person-group><article-title>Variation in <italic toggle="yes">Brucella abortus</italic> 2308 infection in BALB/c mice induced by prior vaccination with salt-extractable periplasmic proteins from <italic toggle="yes">Brucella abortus</italic> 19</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>1996</year><volume>64</volume><issue>2</issue><fpage>548</fpage><lpage>556</lpage><pub-id pub-id-type="other">2-s2.0-0030061539</pub-id><pub-id pub-id-type="pmid">8550206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.64.2.548-556.1996</pub-id><pub-id pub-id-type="pmcid">PMC173800</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>MG</given-names></name><name name-style="western"><surname>Tabatabai</surname><given-names>LB</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Cheville</surname><given-names>NF</given-names></name></person-group><article-title>Immune responses to superoxide dismutase and synthetic peptides of superoxide dismutase in cattle vaccinated with <italic toggle="yes">Brucella abortus</italic> strain 19 or RB51</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>1994</year><volume>41</volume><issue>4</issue><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="other">2-s2.0-0028105963</pub-id><pub-id pub-id-type="pmid">7801538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0378-1135(94)90034-5</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabatabai</surname><given-names>LB</given-names></name><name name-style="western"><surname>Pugh</surname><given-names>GW</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Stevens</surname><given-names>MG</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>M</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>TJ</given-names></name></person-group><article-title>Monophosphoryl lipid A-induced immune enhancement of <italic toggle="yes">Brucella abortus</italic> salt-extractable protein and lipopolysaccharide vaccines in BALB/c mice</article-title><source><italic toggle="yes">American Journal of Veterinary Research</italic></source><year>1992</year><volume>53</volume><issue>10</issue><fpage>1900</fpage><lpage>1907</lpage><pub-id pub-id-type="other">2-s2.0-0026937376</pub-id><pub-id pub-id-type="pmid">1456539</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabatabai</surname><given-names>LB</given-names></name><name name-style="western"><surname>Pugh</surname><given-names>GW</given-names><suffix>Jr.</suffix></name></person-group><article-title>Modulation of immune responses in Balb/c mice vaccinated with <italic toggle="yes">Brucella abortus</italic> Cu-Zn superoxide dismutase synthetic peptide vaccine</article-title><source><italic toggle="yes">Vaccine</italic></source><year>1994</year><volume>12</volume><issue>10</issue><fpage>919</fpage><lpage>924</lpage><pub-id pub-id-type="other">2-s2.0-0028109269</pub-id><pub-id pub-id-type="pmid">7526568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0264-410x(94)90035-3</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desmettre</surname><given-names>P</given-names></name><name name-style="western"><surname>Jouber</surname><given-names>L</given-names></name><name name-style="western"><surname>Valette</surname><given-names>L</given-names></name><name name-style="western"><surname>Roux</surname><given-names>J</given-names></name></person-group><article-title>Vaccin de la brucellose humaine obtenu a partir de la fraction phenolo-insoluble de <italic toggle="yes">Brucella abortus</italic> souche B19. Production, contr&#244;le, standardisation</article-title><source><italic toggle="yes">Developments in Biological Standardization</italic></source><year>1984</year><volume>56</volume><fpage>579</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">6436115</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roux</surname><given-names>J</given-names></name></person-group><article-title>Epidemiology and prevention of brucellosis</article-title><source><italic toggle="yes">Bulletin of the World Health Organization</italic></source><year>1979</year><volume>57</volume><issue>2</issue><fpage>179</fpage><lpage>194</lpage><pub-id pub-id-type="other">2-s2.0-0018763457</pub-id><pub-id pub-id-type="pmid">312154</pub-id><pub-id pub-id-type="pmcid">PMC2395779</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Stoffregen</surname><given-names>WS</given-names></name></person-group><article-title>Essential role of vaccines in brucellosis control and eradication programs for livestock</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2005</year><volume>4</volume><issue>6</issue><fpage>915</fpage><lpage>928</lpage><pub-id pub-id-type="other">2-s2.0-29944447211</pub-id><pub-id pub-id-type="pmid">16372886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.4.6.915</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzetti</surname><given-names>S</given-names></name><name name-style="western"><surname>Carranza</surname><given-names>C</given-names></name><name name-style="western"><surname>Roncallo</surname><given-names>M</given-names></name><name name-style="western"><surname>Escobar</surname><given-names>GI</given-names></name><name name-style="western"><surname>Lucero</surname><given-names>NE</given-names></name></person-group><article-title>Recent trends in human<italic toggle="yes">Brucellacanis</italic>infection</article-title><source><italic toggle="yes">Comparative Immunology, Microbiology and Infectious Disease</italic></source><year>2013</year><volume>36</volume><issue>1</issue><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cimid.2012.09.002</pub-id><pub-id pub-id-type="pmid">23040615</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>SC</given-names></name><name name-style="western"><surname>Giambartolomei</surname><given-names>GH</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name></person-group><article-title>Confronting the barriers to develop novel vaccines against brucellosis</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2011</year><volume>10</volume><issue>9</issue><fpage>1291</fpage><lpage>1305</lpage><pub-id pub-id-type="pmid">21919619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.11.110</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moriy&#243;n</surname><given-names>I</given-names></name><name name-style="western"><surname>Grill&#243;</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Monreal</surname><given-names>D</given-names></name><etal/></person-group><article-title>Rough vaccines in animal brucellosis: structural and genetic basis and present status</article-title><source><italic toggle="yes">, Veterinary Research</italic></source><year>2004</year><volume>35</volume><issue>1</issue><fpage>1</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">15099501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1051/vetres:2003037</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>EL</given-names></name><name name-style="western"><surname>Bracewell</surname><given-names>CD</given-names></name><name name-style="western"><surname>Corbel</surname><given-names>MJ</given-names></name></person-group><article-title>Characterisation of <italic toggle="yes">Brucella abortus</italic> strain 19 cultures isolated from vaccinated cattle</article-title><source><italic toggle="yes">Veterinary Record</italic></source><year>1981</year><volume>108</volume><issue>5</issue><fpage>90</fpage><lpage>93</lpage><pub-id pub-id-type="other">2-s2.0-0019891737</pub-id><pub-id pub-id-type="pmid">6789543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/vr.108.5.90</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>LG</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Adams</surname><given-names>LG</given-names></name></person-group><article-title>Development of live <italic toggle="yes">Brucella</italic> vaccines</article-title><source><italic toggle="yes">Advances of Brucellosis Research</italic></source><year>1990</year><fpage>250</fpage><lpage>256</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Roop</surname><given-names>RM</given-names></name><name name-style="western"><surname>Bagchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>S</given-names></name><name name-style="western"><surname>Buhrman</surname><given-names>D</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name></person-group><article-title>Biological properties of RB51; a stable rough strain of <italic toggle="yes">Brucella abortus</italic>
</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>1991</year><volume>28</volume><issue>2</issue><fpage>171</fpage><lpage>188</lpage><pub-id pub-id-type="other">2-s2.0-0025729450</pub-id><pub-id pub-id-type="pmid">1908158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0378-1135(91)90091-s</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>McQuiston</surname><given-names>JR</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Halling</surname><given-names>SM</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name></person-group><article-title>Identification of an IS711 element interrupting the wboA gene of <italic toggle="yes">Brucella abortus</italic> vaccine strain RB51 and a PCR assay to distinguish strain RB51 from other Brucella species and strains</article-title><source><italic toggle="yes">Clinical and Diagnostic Laboratory Immunology</italic></source><year>1999</year><volume>6</volume><issue>5</issue><fpage>760</fpage><lpage>764</lpage><pub-id pub-id-type="other">2-s2.0-0032874151</pub-id><pub-id pub-id-type="pmid">10473532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/cdli.6.5.760-764.1999</pub-id><pub-id pub-id-type="pmcid">PMC95769</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uzal</surname><given-names>FA</given-names></name><name name-style="western"><surname>Samartino</surname><given-names>L</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>G</given-names></name><etal/></person-group><article-title>Effect of vaccination with <italic toggle="yes">Brucella abortus</italic> strain RB51 on heifers and pregnant cattle</article-title><source><italic toggle="yes">Veterinary Research Communications</italic></source><year>2000</year><volume>24</volume><issue>3</issue><fpage>143</fpage><lpage>151</lpage><pub-id pub-id-type="other">2-s2.0-0034000262</pub-id><pub-id pub-id-type="pmid">10836273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1006468713614</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashford</surname><given-names>DA</given-names></name><name name-style="western"><surname>Di Pietra</surname><given-names>J</given-names></name><name name-style="western"><surname>Lingappa</surname><given-names>J</given-names></name><etal/></person-group><article-title>Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2004</year><volume>22</volume><issue>25-26</issue><fpage>3435</fpage><lpage>3439</lpage><pub-id pub-id-type="other">2-s2.0-4143082695</pub-id><pub-id pub-id-type="pmid">15308369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2004.02.041</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alton</surname><given-names>GG</given-names></name><name name-style="western"><surname>Elberg</surname><given-names>SS</given-names></name></person-group><article-title>Rev 1 <italic toggle="yes">Brucella melitensis</italic> vaccine</article-title><source><italic toggle="yes">Veterinary Bulletin</italic></source><year>1967</year><volume>37</volume><fpage>793</fpage><lpage>800</lpage></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banai</surname><given-names>M</given-names></name></person-group><article-title>Control of small ruminant brucellosis by use of <italic toggle="yes">Brucella melitensis</italic> Rev.1 vaccine: laboratory aspects and field observations</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2002</year><volume>90</volume><issue>1&#8211;4</issue><fpage>497</fpage><lpage>519</lpage><pub-id pub-id-type="other">2-s2.0-0037146616</pub-id><pub-id pub-id-type="pmid">12414167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-1135(02)00231-6</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lord</surname><given-names>VR</given-names></name><name name-style="western"><surname>Cherwonogrodzky</surname><given-names>JW</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Lord</surname><given-names>RD</given-names></name><name name-style="western"><surname>Marcano</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Mel&#233;ndez</surname><given-names>GE</given-names></name></person-group><article-title>Venezuelan field trials of vaccines against brucellosis in swine</article-title><source><italic toggle="yes">American Journal of Veterinary Research</italic></source><year>1998</year><volume>59</volume><issue>5</issue><fpage>546</fpage><lpage>551</lpage><pub-id pub-id-type="other">2-s2.0-0031832202</pub-id><pub-id pub-id-type="pmid">9582954</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="book"><collab>WHO/MZCP</collab><source><italic toggle="yes">Human and Animal Brucellosis</italic></source><year>1998</year><publisher-loc>Damascus, Syria</publisher-loc><publisher-name>WHO</publisher-name></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minas</surname><given-names>A</given-names></name><name name-style="western"><surname>Minas</surname><given-names>M</given-names></name><name name-style="western"><surname>Stournara</surname><given-names>A</given-names></name><name name-style="western"><surname>Tselepidis</surname><given-names>S</given-names></name></person-group><article-title>The &#8220;effects&#8221; of Rev-1 vaccination of sheep and goats on human brucellosis in Greece</article-title><source><italic toggle="yes">Preventive Veterinary Medicine</italic></source><year>2004</year><volume>64</volume><issue>1</issue><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="other">2-s2.0-3042802207</pub-id><pub-id pub-id-type="pmid">15219968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.prevetmed.2004.03.007</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Refai</surname><given-names>M</given-names></name></person-group><article-title>Incidence and control of brucellosis in the Near East region</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2002</year><volume>90</volume><issue>1&#8211;4</issue><fpage>81</fpage><lpage>110</lpage><pub-id pub-id-type="other">2-s2.0-0037146666</pub-id><pub-id pub-id-type="pmid">12414137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-1135(02)00248-1</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>HN</given-names></name><name name-style="western"><surname>Belden</surname><given-names>RC</given-names></name><name name-style="western"><surname>Breault</surname><given-names>T</given-names></name><etal/></person-group><article-title>Brucellosis in feral swine in Florida</article-title><source><italic toggle="yes">Journal of the American Veterinary Medical Association</italic></source><year>1978</year><volume>173</volume><issue>9</issue><fpage>1181</fpage><lpage>1182</lpage><pub-id pub-id-type="other">2-s2.0-0018070590</pub-id><pub-id pub-id-type="pmid">738942</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Godfroid</surname><given-names>J</given-names></name><name name-style="western"><surname>K&#228;sbohrer</surname><given-names>A</given-names></name></person-group><article-title>Brucellosis in the European Union and Norway at the turn of the twenty-first century</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2002</year><volume>90</volume><issue>1&#8211;4</issue><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">12414139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-1135(02)00217-1</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Costa Martins</surname><given-names>R</given-names></name><name name-style="western"><surname>Irache</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gamazo</surname><given-names>C</given-names></name></person-group><article-title>Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2012</year><volume>11</volume><issue>1</issue><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">22149711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.11.172</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arsenault</surname><given-names>J</given-names></name><name name-style="western"><surname>Girard</surname><given-names>C</given-names></name><name name-style="western"><surname>Dubreuil</surname><given-names>P</given-names></name><name name-style="western"><surname>B&#233;langer</surname><given-names>D</given-names></name></person-group><article-title>Lack of evidence of <italic toggle="yes">Brucella ovis</italic> infection in rams in Quebec</article-title><source><italic toggle="yes">The Canadian Veterinary Journal</italic></source><year>2004</year><volume>45</volume><issue>4</issue><fpage>312</fpage><lpage>313</lpage><pub-id pub-id-type="other">2-s2.0-2442602374</pub-id><pub-id pub-id-type="pmid">15144103</pub-id><pub-id pub-id-type="pmcid">PMC548616</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perkins</surname><given-names>SD</given-names></name><name name-style="western"><surname>Smither</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>HS</given-names></name></person-group><article-title>Towards a <italic toggle="yes">Brucella</italic> vaccine for humans</article-title><source><italic toggle="yes">FEMS Microbiology Reviews</italic></source><year>2010</year><volume>34</volume><issue>3</issue><fpage>379</fpage><lpage>394</lpage><pub-id pub-id-type="other">2-s2.0-77950380555</pub-id><pub-id pub-id-type="pmid">20180858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1574-6976.2010.00211.x</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Iba&#241;ez</surname><given-names>AE</given-names></name><name name-style="western"><surname>Coria</surname><given-names>LM</given-names></name><etal/></person-group><article-title>An oral vaccine based on U-Omp19 induces protection against <italic toggle="yes">B. abortus</italic> mucosal challenge by inducing an adaptive IL-17 immune response in mice</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2011</year><volume>6</volume><issue>1, article e16203</issue><pub-id pub-id-type="other">2-s2.0-79251592270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0016203</pub-id><pub-id pub-id-type="pmcid">PMC3021544</pub-id><pub-id pub-id-type="pmid">21264260</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fugier</surname><given-names>E</given-names></name><name name-style="western"><surname>Pappas</surname><given-names>G</given-names></name><name name-style="western"><surname>Gorvel</surname><given-names>JP</given-names></name></person-group><article-title>Virulence factors in brucellosis: implications for aetiopathogenesis and treatment</article-title><source><italic toggle="yes">Expert Reviews in Molecular Medicine</italic></source><year>2007</year><volume>9</volume><issue>35</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="other">2-s2.0-38449119589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S1462399407000543</pub-id><pub-id pub-id-type="pmid">18088444</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Samartino</surname><given-names>CG</given-names></name><name name-style="western"><surname>Coria</surname><given-names>LM</given-names></name><etal/></person-group><article-title>The protein moiety of <italic toggle="yes">Brucella abortus</italic> outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells <italic toggle="yes">in vivo</italic>, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2010</year><volume>184</volume><issue>9</issue><fpage>5200</fpage><lpage>5212</lpage><pub-id pub-id-type="other">2-s2.0-77954477951</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0902209</pub-id><pub-id pub-id-type="pmid">20351187</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruecker</surname><given-names>C</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>CA</given-names></name></person-group><article-title>Vaccines: from empirical development to rational desing</article-title><source><italic toggle="yes">PLOS Pathogens</italic></source><year>2012</year><volume>8</volume><issue>11</issue><pub-id pub-id-type="publisher-id">e1003001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1003001</pub-id><pub-id pub-id-type="pmcid">PMC3493475</pub-id><pub-id pub-id-type="pmid">23144616</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delvecchio</surname><given-names>VG</given-names></name><name name-style="western"><surname>Alefantis</surname><given-names>T</given-names></name><name name-style="western"><surname>Ugalde</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Identification of protein candidates for developing bacterial ghost vaccines against <italic toggle="yes">Brucella</italic>
</article-title><source><italic toggle="yes">Methods of Biochemical Analysis</italic></source><year>2006</year><volume>49</volume><fpage>363</fpage><lpage>377</lpage><pub-id pub-id-type="other">2-s2.0-33749064150</pub-id><pub-id pub-id-type="pmid">16929687</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Vaccination with the recombinant <italic toggle="yes">Brucella</italic> outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against <italic toggle="yes">Brucella melitensis</italic> infection</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2005</year><volume>73</volume><issue>12</issue><fpage>8079</fpage><lpage>8088</lpage><pub-id pub-id-type="other">2-s2.0-28444434119</pub-id><pub-id pub-id-type="pmid">16299302</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.73.12.8079-8088.2005</pub-id><pub-id pub-id-type="pmcid">PMC1307072</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edmonds</surname><given-names>MD</given-names></name><name name-style="western"><surname>Cloeckaert</surname><given-names>A</given-names></name><name name-style="western"><surname>Elzer</surname><given-names>PH</given-names></name></person-group><article-title>
<italic toggle="yes">Brucella</italic> species lacking the major outer membrane protein Omp25 are attenuated in mice and protect against <italic toggle="yes">Brucella melitensis</italic> and <italic toggle="yes">Brucella ovis</italic>
</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2002</year><volume>88</volume><issue>3</issue><fpage>205</fpage><lpage>221</lpage><pub-id pub-id-type="other">2-s2.0-0037009220</pub-id><pub-id pub-id-type="pmid">12151196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-1135(02)00110-4</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goel</surname><given-names>D</given-names></name><name name-style="western"><surname>Bhatnagar</surname><given-names>R</given-names></name></person-group><article-title>Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent <italic toggle="yes">B. abortus</italic> 544</article-title><source><italic toggle="yes">Molecular Immunology</italic></source><year>2012</year><volume>51</volume><issue>2</issue><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">22464098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2012.02.126</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delpino</surname><given-names>MV</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name></person-group><article-title>Vaccination with <italic toggle="yes">Brucella</italic> recombinant DnaK and SurA proteins induces protection against <italic toggle="yes">Brucella abortus</italic> infection in BALB/c mice</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2007</year><volume>25</volume><issue>37-38</issue><fpage>6721</fpage><lpage>6729</lpage><pub-id pub-id-type="other">2-s2.0-34548321638</pub-id><pub-id pub-id-type="pmid">17686554</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.07.002</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><etal/></person-group><article-title>A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against <italic toggle="yes">B. ovis</italic> than Rev.1 vaccination</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2007</year><volume>25</volume><issue>22</issue><fpage>4437</fpage><lpage>4446</lpage><pub-id pub-id-type="other">2-s2.0-34247872947</pub-id><pub-id pub-id-type="pmid">17442465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.03.028</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mariri</surname><given-names>A</given-names></name><name name-style="western"><surname>Tibor</surname><given-names>A</given-names></name><name name-style="western"><surname>Mertens</surname><given-names>P</given-names></name><etal/></person-group><article-title>Protection of BALB/c mice against <italic toggle="yes">Brucella abortus</italic> 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2001</year><volume>69</volume><issue>8</issue><fpage>4816</fpage><lpage>4822</lpage><pub-id pub-id-type="other">2-s2.0-0034927083</pub-id><pub-id pub-id-type="pmid">11447155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.69.8.4816-4822.2001</pub-id><pub-id pub-id-type="pmcid">PMC98569</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaushik</surname><given-names>P</given-names></name><name name-style="western"><surname>Singh</surname><given-names>DK</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Protection of mice against <italic toggle="yes">Brucella abortus</italic> 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides</article-title><source><italic toggle="yes">Veterinary Research Communications</italic></source><year>2010</year><volume>34</volume><issue>2</issue><fpage>119</fpage><lpage>132</lpage><pub-id pub-id-type="other">2-s2.0-77952550263</pub-id><pub-id pub-id-type="pmid">20013309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11259-009-9337-x</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>VK</given-names></name><name name-style="western"><surname>Radhakrishnan</surname><given-names>G</given-names></name><name name-style="western"><surname>Harms</surname><given-names>J</given-names></name><name name-style="western"><surname>Splitter</surname><given-names>G</given-names></name></person-group><article-title>Invasive <italic toggle="yes">Escherichia coli</italic> vaccines expressing <italic toggle="yes">Brucella melitensis</italic> outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with <italic toggle="yes">B. melitensis</italic>
</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2012</year><volume>30</volume><issue>27</issue><fpage>4017</fpage><lpage>4022</lpage><pub-id pub-id-type="pmid">22546330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.04.036</pub-id><pub-id pub-id-type="pmcid">PMC3361596</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;ez</surname><given-names>D</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>P</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>A</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A</given-names></name></person-group><article-title>Oral immunization of mice with recombinant <italic toggle="yes">Lactococcus lactis</italic> expressing Cu, Zn superoxide dismutase of <italic toggle="yes">Brucella abortus</italic> triggers protective immunity</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2012</year><volume>30</volume><issue>7</issue><fpage>1283</fpage><lpage>1290</lpage><pub-id pub-id-type="pmid">22222868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.12.088</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#241;ate</surname><given-names>AA</given-names></name><name name-style="western"><surname>Donoso</surname><given-names>G</given-names></name><name name-style="western"><surname>Moraga-Cid</surname><given-names>G</given-names></name><name name-style="western"><surname>Folch</surname><given-names>H</given-names></name><name name-style="western"><surname>C&#233;spedes</surname><given-names>S</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name></person-group><article-title>An RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu,Zn superoxide dismutase protein of <italic toggle="yes">Brucella abortus</italic> induces protective immunity in BALB/c mice</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2005</year><volume>73</volume><issue>6</issue><fpage>3294</fpage><lpage>3300</lpage><pub-id pub-id-type="other">2-s2.0-19744374114</pub-id><pub-id pub-id-type="pmid">15908354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.73.6.3294-3300.2005</pub-id><pub-id pub-id-type="pmcid">PMC1111843</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baloglu</surname><given-names>S</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Schurig</surname><given-names>GG</given-names></name><name name-style="western"><surname>Toth</surname><given-names>TE</given-names></name></person-group><article-title>Immune responses of mice to vaccinia virus recombinants expressing either <italic toggle="yes">Listeria monocytogenes</italic> partial listeriolysin or <italic toggle="yes">Brucella abortus</italic> ribosomal L7/L12 protein</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2005</year><volume>109</volume><issue>1-2</issue><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="other">2-s2.0-21744455459</pub-id><pub-id pub-id-type="pmid">15941627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vetmic.2005.04.011</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Velikovsky</surname><given-names>CA</given-names></name><name name-style="western"><surname>de La Barrera</surname><given-names>S</given-names></name><etal/></person-group><article-title>A DNA vaccine coding for the <italic toggle="yes">Brucella</italic> outer membrane protein 31 confers protection against <italic toggle="yes">B. melitensis</italic> and <italic toggle="yes">B. ovis</italic> infection by eliciting a specific cytotoxic response</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2005</year><volume>73</volume><issue>10</issue><fpage>6537</fpage><lpage>6546</lpage><pub-id pub-id-type="other">2-s2.0-25444524000</pub-id><pub-id pub-id-type="pmid">16177328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.73.10.6537-6546.2005</pub-id><pub-id pub-id-type="pmcid">PMC1230944</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velikovsky</surname><given-names>CA</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Giambartolomei</surname><given-names>GH</given-names></name><etal/></person-group><article-title>A DNA vaccine encoding lumazine synthase from <italic toggle="yes">Brucella abortus</italic> induces protective immunity in BALB/c mice</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2002</year><volume>70</volume><issue>5</issue><fpage>2507</fpage><lpage>2511</lpage><pub-id pub-id-type="other">2-s2.0-0036121919</pub-id><pub-id pub-id-type="pmid">11953389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.70.5.2507-2511.2002</pub-id><pub-id pub-id-type="pmcid">PMC127889</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>D</given-names></name><name name-style="western"><surname>Ni</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><etal/></person-group><article-title>Protective immunity elicited by a divalent DNA vaccine encoding both the L7/L12 and Omp16 genes of <italic toggle="yes">Brucella abortus</italic> in BALB/c mice</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2006</year><volume>74</volume><issue>5</issue><fpage>2734</fpage><lpage>2741</lpage><pub-id pub-id-type="other">2-s2.0-33646359172</pub-id><pub-id pub-id-type="pmid">16622210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.74.5.2734-2741.2006</pub-id><pub-id pub-id-type="pmcid">PMC1459688</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>DY</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Xing</surname><given-names>L</given-names></name><etal/></person-group><article-title>DNA vaccine encoding L7/L12-P39 of <italic toggle="yes">Brucella abortus</italic> induces protective immunity in BALB/c mice</article-title><source><italic toggle="yes">Chinese Medical Journal</italic></source><year>2006</year><volume>119</volume><issue>4</issue><fpage>331</fpage><lpage>334</lpage><pub-id pub-id-type="other">2-s2.0-33645292375</pub-id><pub-id pub-id-type="pmid">16537031</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>DH</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>XD</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name></person-group><article-title>A combined DNA vaccine enhances protective immunity against <italic toggle="yes">Mycobacterium tuberculosis</italic> and <italic toggle="yes">Brucella abortus</italic> in the presence of an IL-12 expression vector</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2007</year><volume>25</volume><issue>37-38</issue><fpage>6744</fpage><lpage>6754</lpage><pub-id pub-id-type="other">2-s2.0-34548292484</pub-id><pub-id pub-id-type="pmid">17681650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.06.061</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Smith</surname><given-names>A</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>E</given-names></name><name name-style="western"><surname>O&#241;ate</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of <italic toggle="yes">Brucella abortus</italic> DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2</article-title><source><italic toggle="yes">Immunobiology</italic></source><year>2006</year><volume>211</volume><issue>1-2</issue><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="other">2-s2.0-31544432038</pub-id><pub-id pub-id-type="pmid">16446171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.imbio.2005.09.004</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singha</surname><given-names>H</given-names></name><name name-style="western"><surname>Mallick</surname><given-names>AI</given-names></name><name name-style="western"><surname>Jana</surname><given-names>C</given-names></name><etal/></person-group><article-title>Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against <italic toggle="yes">Brucella abortus</italic>
</article-title><source><italic toggle="yes">Microbes and Infection</italic></source><year>2008</year><volume>10</volume><issue>10-11</issue><fpage>1089</fpage><lpage>1096</lpage><pub-id pub-id-type="other">2-s2.0-54049123216</pub-id><pub-id pub-id-type="pmid">18602490</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2008.05.007</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>XD</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ST</given-names></name><name name-style="western"><surname>Li</surname><given-names>JY</given-names></name><name name-style="western"><surname>Yu</surname><given-names>DH</given-names></name><name name-style="western"><surname>Yi-zhang</surname></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name></person-group><article-title>An IL-15 adjuvant enhances the efficacy of a combined DNA vaccine against <italic toggle="yes">Brucella</italic> by increasing the CD8+ cytotoxic T cell response</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2010</year><volume>28</volume><issue>12</issue><fpage>2408</fpage><lpage>2415</lpage><pub-id pub-id-type="other">2-s2.0-77249178689</pub-id><pub-id pub-id-type="pmid">20064480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2009.12.076</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>DH</given-names></name><name name-style="western"><surname>Hu</surname><given-names>XD</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name></person-group><article-title>A combined DNA vaccine encoding BCSP31, SOD, and L7/L12 confers high protection against <italic toggle="yes">Brucella abortus</italic> 2308 by inducing specific CTL responses</article-title><source><italic toggle="yes">DNA and Cell Biology</italic></source><year>2007</year><volume>26</volume><issue>6</issue><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="other">2-s2.0-34250792187</pub-id><pub-id pub-id-type="pmid">17570767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/dna.2006.0552</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amano</surname><given-names>A</given-names></name><name name-style="western"><surname>Takeuchi</surname><given-names>H</given-names></name><name name-style="western"><surname>Furuta</surname><given-names>N</given-names></name></person-group><article-title>Outer membrane vesicles function as offensive weapons in host-parasite interactions</article-title><source><italic toggle="yes">Microbes and Infection</italic></source><year>2010</year><volume>12</volume><issue>11</issue><fpage>791</fpage><lpage>798</lpage><pub-id pub-id-type="other">2-s2.0-77957752025</pub-id><pub-id pub-id-type="pmid">20685339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2010.05.008</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beveridge</surname><given-names>TJ</given-names></name></person-group><article-title>Structures of gram-negative cell walls and their derived membrane vesicles</article-title><source><italic toggle="yes">Journal of Bacteriology</italic></source><year>1999</year><volume>181</volume><issue>16</issue><fpage>4725</fpage><lpage>4733</lpage><pub-id pub-id-type="other">2-s2.0-0032839616</pub-id><pub-id pub-id-type="pmid">10438737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jb.181.16.4725-4733.1999</pub-id><pub-id pub-id-type="pmcid">PMC93954</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>TN</given-names></name><name name-style="western"><surname>Kuehn</surname><given-names>MJ</given-names></name></person-group><article-title>Virulence and immunomodulatory roles of bacterial outer membrane vesicles</article-title><source><italic toggle="yes">Microbiology and Molecular Biology Reviews</italic></source><year>2010</year><volume>74</volume><issue>1</issue><fpage>81</fpage><lpage>94</lpage><pub-id pub-id-type="other">2-s2.0-77749309281</pub-id><pub-id pub-id-type="pmid">20197500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/MMBR.00031-09</pub-id><pub-id pub-id-type="pmcid">PMC2832350</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuehn</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kesty</surname><given-names>NC</given-names></name></person-group><article-title>Bacterial outer membrane vesicles and the host-pathogen interaction</article-title><source><italic toggle="yes">Genes and Development</italic></source><year>2005</year><volume>19</volume><issue>22</issue><fpage>2645</fpage><lpage>2655</lpage><pub-id pub-id-type="other">2-s2.0-27744480818</pub-id><pub-id pub-id-type="pmid">16291643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.1299905</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mashburn-Warren</surname><given-names>LM</given-names></name><name name-style="western"><surname>Whiteley</surname><given-names>M</given-names></name></person-group><article-title>Special delivery: vesicle trafficking in prokaryotes</article-title><source><italic toggle="yes">Molecular Microbiology</italic></source><year>2006</year><volume>61</volume><issue>4</issue><fpage>839</fpage><lpage>846</lpage><pub-id pub-id-type="other">2-s2.0-33746561249</pub-id><pub-id pub-id-type="pmid">16879642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2958.2006.05272.x</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unal</surname><given-names>CM</given-names></name><name name-style="western"><surname>Schaar</surname><given-names>V</given-names></name><name name-style="western"><surname>Riesbeck</surname><given-names>K</given-names></name></person-group><article-title>Bacterial outer membrane vesicles in disease and preventive medicine</article-title><source><italic toggle="yes">Seminars in Immunopathology</italic></source><year>2011</year><volume>33</volume><issue>5</issue><fpage>395</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">21153593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00281-010-0231-y</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boigegrain</surname><given-names>RA</given-names></name><name name-style="western"><surname>Salhi</surname><given-names>I</given-names></name><name name-style="western"><surname>Alvarez-Martinez</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Release of periplasmic proteins of <italic toggle="yes">Brucella suis</italic> upon acidic shock involves the outer membrane protein Omp25</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2004</year><volume>72</volume><issue>10</issue><fpage>5693</fpage><lpage>5703</lpage><pub-id pub-id-type="other">2-s2.0-4644359498</pub-id><pub-id pub-id-type="pmid">15385468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.72.10.5693-5703.2004</pub-id><pub-id pub-id-type="pmcid">PMC517528</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gamazo</surname><given-names>C</given-names></name><name name-style="western"><surname>Winter</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Moriyon</surname><given-names>I</given-names></name><name name-style="western"><surname>Riezu-Boj</surname><given-names>JI</given-names></name><name name-style="western"><surname>Blasco</surname><given-names>JM</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>R</given-names></name></person-group><article-title>Comparative analyses of proteins extracted by hot saline or released spontaneously into outer membrane blebs from field strains of <italic toggle="yes">Brucella ovis</italic> and <italic toggle="yes">Brucella melitensis</italic>
</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>1989</year><volume>57</volume><issue>5</issue><fpage>1419</fpage><lpage>1426</lpage><pub-id pub-id-type="other">2-s2.0-0024517697</pub-id><pub-id pub-id-type="pmid">2651307</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.57.5.1419-1426.1989</pub-id><pub-id pub-id-type="pmcid">PMC313293</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avila-Calder&#243;n</surname><given-names>ED</given-names></name><name name-style="western"><surname>Lopez-Merino</surname><given-names>A</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N</given-names></name><etal/></person-group><article-title>Characterization of outer membrane vesicles from <italic toggle="yes">Brucella melitensis</italic> and protection induced in mice</article-title><source><italic toggle="yes">Clinical and Developmental Immunology</italic></source><year>2012</year><volume>2012</volume><pub-id pub-id-type="publisher-id">352493</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2012/352493</pub-id><pub-id pub-id-type="pmcid">PMC3254011</pub-id><pub-id pub-id-type="pmid">22242036</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain-Gupta</surname><given-names>N</given-names></name><name name-style="western"><surname>Contreras-Rodriguez</surname><given-names>A</given-names></name><name name-style="western"><surname>Vemulapalli</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against <italic toggle="yes">Brucella melitensis</italic> challenge in mice</article-title><source><italic toggle="yes">FEMS Immunology and Medical Microbiology</italic></source><year>2012</year><volume>66</volume><issue>3</issue><fpage>436</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">23163875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1574-695X.12010</pub-id><pub-id pub-id-type="pmcid">PMC4426994</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollak</surname><given-names>CN</given-names></name><name name-style="western"><surname>Delpino</surname><given-names>MV</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name></person-group><article-title>Outer membrane vesicles from <italic toggle="yes">Brucella abortus</italic> promote bacterial internalization by human monocytes and modulate their innate immune response</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2012</year><volume>7</volume><issue>11</issue><pub-id pub-id-type="publisher-id">e50214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0050214</pub-id><pub-id pub-id-type="pmcid">PMC3506553</pub-id><pub-id pub-id-type="pmid">23189190</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>